ReviewSignal transduction and targeted therapy2026
Deciphering the regulatory landscape of enhancer RNAs in health and disease.
Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- 3D Genome Engineering Using CRISPR/dCas Systems.International journal of molecular sciences · 2026Review
- Enhancer RNA transcription near segmentation gene enhancers can be analyzed in situ using FISH.G3 (Bethesda, Md.) · 2026Article
- The case for targeting enhancer regions in high-risk TCF3::HLF-positive B-cell acute lymphoblastic leukemia.HemaSphere · 2026Article
- Nucleotide resolution 4-thiouridine sequencing by SNU-Seq and sf4sU-Seq reveals the transcriptional responsiveness of an epigenetically primed human genome.Nucleic acids research · 2026Article
- Article
- Unravelling the nexus of non-coding RNAs in cancer stemness and therapeutic drug resistance.Frontiers in cell and developmental biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enhancers are distal cis-regulatory elements that orchestrate spatiotemporal gene expression patterns in response to developmental cues and environmental stimuli. Genetic and epigenetic alterations in enhancers are associated with the initiation and progression of human diseases, including cancers. Over the past few decades, accumulating evidence has revealed that a class of nascent RNA transcripts, known as enhancer RNAs (eRNAs), is broadly transcribed from active enhancers. These eRNA species contribute to complex and dynamic gene regulatory networks under both physiological and pathological conditions through diverse mechanisms. Notably, dysregulated eRNA expression has been reported across various cancer types and is often correlated with patient survival outcomes. Consequently, eRNAs are emerging as promising biomarkers and therapeutic targets for cancer treatment. This review provides a comprehensive summary of the current understanding of eRNAs and their mechanisms of action in gene regulation. We discuss the critical roles of eRNAs in both health and disease and highlight their diagnostic and prognostic value, as well as their therapeutic potential in cancer. Additionally, we review current strategies for targeting RNA transcripts, including eRNAs, and discuss the major challenges in developing eRNA-targeted therapies. Finally, we propose future directions for advancing eRNA-based interventions in the treatment of human diseases, including cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.